Sana Biotechnology, Inc. — Form D
Sana Biotechnology, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2020-06-26. The offering totals $821.1M, of which $821.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-06-26
- Form: D
- Accession: 0001770121-20-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $821.1M
- Amount sold: $821.1M
- Investors: 40
- Date of first sale: 2019-02-13
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-369787
Issuer
- Name: Sana Biotechnology, Inc.
- CIK: 0001770121
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 188 EAST BLAINE STREET, SUIT 400, SEATTLE, WA, 98102
- Phone: (206) 701-7914
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Hans J Bishop | Director | SEATTLE, WA |
| Douglas J Cole | Director | SEATTLE, WA |
| Steven D Harr | Director | SEATTLE, WA |
| Stephen J Knight | Director | SEATTLE, WA |
| Richard J Mulligan | Director | SEATTLE, WA |
| Robert J Nelsen | Director | SEATTLE, WA |
| Donald J Payan | Director | SEATTLE, WA |
| Geoffrey J von Maltzahn | Director | SEATTLE, WA |
| Mary Agnes J Wilderotter | Director | SEATTLE, WA |
| Patrick J Yang | Director | SEATTLE, WA |
| Nathan D Hardy | Executive Officer | SEATTLE, WA |
| Steven D Harr | Executive Officer | SEATTLE, WA |
| James J MacDonald | Executive Officer | SEATTLE, WA |
Other filings by this issuer (1)
More